Dacomitinib Approaches EU Approval for EGFR+ NSCLC

February 1, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dacomitinib for the frontline treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the manufacturer of the pan-human EGFR TKI. The CHMP recommendation was based on findings from the phase III ARCHER 1050 trial, in which dacomitinib … (leggi tutto)